292 related articles for article (PubMed ID: 17638068)
41. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant targeted therapy in early breast cancer.
Mackey J; McLeod D; Ragaz J; Gelmon K; Verma S; Pritchard K; Laing K; Provencher L; Charbonneau LF
Cancer; 2009 Mar; 115(6):1154-68. PubMed ID: 19165856
[TBL] [Abstract][Full Text] [Related]
43. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
45. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
46. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
47. Trastuzumab-induced cardiotoxicity.
Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
[TBL] [Abstract][Full Text] [Related]
48. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
Witzel I; Kantelhardt EJ; Milde-Langosch K; Ihnen M; Zeitz J; Harbeck N; Jänicke F; Müller V
Onkologie; 2011; 34(6):304-8. PubMed ID: 21625183
[TBL] [Abstract][Full Text] [Related]
49. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
50. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
51. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
52. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
[TBL] [Abstract][Full Text] [Related]
53. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
[TBL] [Abstract][Full Text] [Related]
54. Trastuzumab versus lapatinib: the cardiac side of the story.
Azim H; Azim HA; Escudier B
Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
[TBL] [Abstract][Full Text] [Related]
55. [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations].
Tanz R; Mahfoud T; Bazine A; Khmamouch R; Bensouda Y; Ismaili N; Benjaafar N; El Gueddari BK; Ichou M; Errihani H
J Gynecol Obstet Biol Reprod (Paris); 2011 Apr; 40(2):144-8. PubMed ID: 21227599
[TBL] [Abstract][Full Text] [Related]
56. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
[TBL] [Abstract][Full Text] [Related]
57. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Yardley DA
Clin Breast Cancer; 2010 Apr; 10(2):119-29. PubMed ID: 20353933
[TBL] [Abstract][Full Text] [Related]
58. Management of trastuzumab-related cardiac dysfunction.
Carver JR
Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
[TBL] [Abstract][Full Text] [Related]
59. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.
Sandoo A; Kitas GD; Carmichael AR
Anticancer Res; 2014 Mar; 34(3):1147-51. PubMed ID: 24596352
[TBL] [Abstract][Full Text] [Related]
60. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]